(Press-News.org) (TORONTO, Canada – Sept. 9, 2013) – Clinical researchers at Princess Margaret Cancer Centre have discovered why multiple myeloma, an incurable cancer of the bone marrow, persistently escapes cure by an initially effective treatment that can keep the disease at bay for up to several years.
The reason, explains research published online today in Cancer Cell, is intrinsic resistance found in immature progenitor cells that are the root cause of the disease – and relapse – says principal investigator Dr. Rodger Tiedemann, a hematologist specializing in multiple myeloma and lymphoma at the Princess Margaret, University Health Network (UHN). Dr. Tiedemann is also an Assistant Professor in the Faculty of Medicine, University of Toronto.
The research demonstrates that the progenitor cells are untouched by mainstay therapy that uses a proteasome inhibitor drug ("Velcade") to kill the plasma cells that make up most of the tumour. The progenitor cells then proliferate and mature to reboot the disease process, even in patients who appeared to be in complete remission.
"Our findings reveal a way forward toward a cure for multiple myeloma, which involves targeting both the progenitor cells and the plasma cells at the same time," says Dr. Tiedemann. "Now that we know that progenitor cells persist and lead to relapse after treatment, we can move quickly into clinical trials, measure this residual disease in patients, and attempt to target it with new drugs or with drugs that may already exist. Dr. Tiedemann talks about his findings in this video: http://www.youtube.com/watch?v=yy2HKCZYbBc.
In tackling the dilemma of treatment failure, the researchers identified a cancer cell maturation hierarchy within multiple myeloma tumors and demonstrated the critical role of myeloma cell maturation in proteasome inhibitor sensitivity. The implication is clear for current drug research focused on developing new proteasome inhibitors: targeting this route alone will never cure multiple myeloma.
Dr. Tiedemann says: "If you think of multiple myeloma as a weed, then proteasome inhibitors such as Velcade are like a persnickety goat that eats the mature foliage above ground, producing a remission, but doesn't eat the roots, so that one day the weed returns."
The research team initially analyzed high-throughput screening assays of 7,500 genes in multiple myeloma cells to identify effectors of drug response, and then studied bone marrow biopsies from patients to further understand their results. The process identified two genes (IRE1 and XBP1) that modulate response to the proteasome inhibitor Velcade and the mechanism underlying the drug resistance that is the barrier to cure.
Dr. Tiedemann is part of the latest generation of cancer researchers at UHN building on the international legacy of Drs. James Till and the late Ernest McCulloch, who pioneered a new field of science in 1961 with their discovery that some cells ("stem cells") can self-renew repeatedly.
The science has continued to advance unabated ever since, and notably with key discoveries by Dr. John Dick of cancer stem cells first in leukemia and next in colon cancer. Dr. Tiedemann's new findings underscore the clinical importance of understanding how cells are organized in the disease process.
INFORMATION:
The research was funded by the Canadian Cancer Society, the Molly and David Bloom Chair in Multiple Myeloma Research, the Arthur Macaulay Cushing Estate and The Princess Margaret Cancer Foundation.
About the Princess Margaret Cancer Centre, University Health Network
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute. All are research hospitals affiliated with the University of Toronto. For more information, go to http://www.theprincessmargaret.ca or http://www.uhn.ca .
Cancer researchers discover root cause of multiple myeloma relapse
2013-09-09
ELSE PRESS RELEASES FROM THIS DATE:
Breath tests could be used to diagnose lung cancer
2013-09-09
Barcelona, Spain: Collecting samples of exhaled breath from people at a high risk of lung cancer could be a cheap and non-invasive method of diagnosing the disease, according to new research.
The findings will be presented today (9 September 2013) at the European Respiratory Society (ERS) Annual Congress in Barcelona.
Current tests for lung cancer include blood and urine tests, followed by CT scans and chest radiographs. This new method could see people at a high risk of lung cancer receiving an initial breath test to quickly assess their symptoms.
Previous research ...
Severe asthma patients less responsive to treatment
2013-09-09
Barcelona, Spain: People with severe asthma, who are often described as 'steroid-dependent', are actually less likely to respond to the treatment they depend on, when compared to people with mild asthma.
The study, presented at the European Respiratory Society (ERS) Annual Congress in Barcelona today (9 September 2013), represents the first analysis of a cohort of patients from an unparalleled research project that will collect over 3 million samples from 300 children and 700 adults with severe and non-severe asthma, and without asthma.
Although asthma is common, ...
Severity of sleep apnea predicts aggressiveness of melanoma
2013-09-09
Barcelona, Spain: The severity of sleep apnoea can independently predict the aggressiveness of malignant skin melanoma, according to a new study.
The research, presented today (9 September 2013) at the European Respiratory Society (ERS) Annual Congress, adds new evidence to a number of studies that have found a link between cancer and the sleep disorder.
Previous studies have looked at a link between sleep apnoea and both mortality and incidence rates from cancer. Some experimental studies in mice have also shown that reduced oxygen levels in the blood, which is common ...
New muscular dystrophy treatment shows promise in early study
2013-09-09
HEIDELBERG -- A preclinical study led by researchers in the United States has found that a new oral drug shows early promise for the treatment of muscular dystrophy. The results, which are published today in EMBO Molecular Medicine, show that VBP15 decreases inflammation in mice with symptoms similar to those found in patients with Duchenne muscular dystrophy. The authors found that the drug protects and strengthens muscle without the harsh side effects linked to current treatments with glucocorticoids such as prednisone.
Duchenne muscular dystrophy results in severe ...
First animal model of adult-onset SMA sheds light on disease progression & treatment
2013-09-09
Cold Spring Harbor, NY – A research team at Cold Spring Harbor Laboratory (CSHL) has used a recently developed technology they call TSUNAMI to create the first animal model of the adult-onset version of spinal muscular atrophy (SMA), a devastating motor-neuron illness.
The same team, led by CSHL Professor Adrian R. Krainer, Ph.D., and including scientists from California-based Isis Pharmaceuticals, as well as the University of Southern California and Stony Brook University, succeeded a year ago in using TSUNAMI to make a mouse model of the disease as it is manifest in ...
MRI spectroscopy is highly sensitive for lipid-soluble metabolites from UC-MSCs
2013-09-09
The water-soluble metabolite profile of human mesenchymal stem cells is known, but the lipid profile remains unclear. Haiyang Dai and colleagues from Shantou University Medical College used methanol-chloroform and perchloric acid to extract lipid-soluble metabolites and water-soluble metabolites, respectively. Furthermore, a dual phase extraction method using methanol-chloroform and water was used to obtain both water and lipid fractions simultaneously. Among the different extraction procedures, perchloric acid was more efficient in extracting water-soluble metabolites ...
Role of autophagic and lysosomal pathways in ischemic brain injury
2013-09-09
Previous studies by Shaohua Gu and team from Shanghai Pudong New Area Zhoupu Hospital showed that rapamycin-induced autophagy decreased the rate of apoptosis, but the rate of apoptosis was increased after the autophagy inhibitor, 3-methyladenine, was used, indicating autophagy may be involved in mediating neuronal death in cerebral ischemia. A recent study reported by Gu et al showed that autophagic and lysosomal activity is increased in ischemic neurons, and the activation of autophagic and lysosomal pathways can provide nutrition and energy for the survival of ischemic ...
Combined treatment shows a better curative effect on spinal cord contusion
2013-09-09
Following spinal cord injury, astrocyte proliferation and scar formation are the main factors inhibiting the regeneration and growth of spinal cord axons, leading to motor and sensory function loss below the level of spinal cord injury. Cell transplantation, bioengineering technology, drugs and other methods can reduce voids of injured spinal cord and suppress glial scar formation, but clinical application results show these methods used alone have no obvious effects. Liang Wu and colleagues from Capital Medical University used rat models of T8 spinal cord contusion, which ...
Stanford scientists calculate the energy required to store wind and solar power on the grid
2013-09-09
Renewable energy holds the promise of reducing carbon dioxide emissions. But there are times when solar and wind farms generate more electricity than is needed by consumers. Storing that surplus energy in batteries for later use seems like an obvious solution, but a new study from Stanford University suggests that might not always be the case.
"We looked at batteries and other promising technologies for storing solar and wind energy on the electrical grid," said Charles Barnhart, the lead author of the study and a postdoctoral scholar at Stanford's Global Climate and ...
Singapore scientists discover new RNA processing pathway important in human embryonic stem cells
2013-09-09
09 Sept 2013 - Scientists at A*STAR's Genome Institute of Singapore (GIS), in collaboration with their counterparts from Canada, Hong Kong and US, have discovered a protein mediator SON plays a critical role in the health and proper functioning of human embryonic stem cells (hESCs). This finding was reported on 8th September 2013 in the advanced online issue of the prestigious science journal Nature Cell Biology.
Correct expression of genes is essential for a cell to stay alive and to perform other cellular and physiological functions. During gene expression, DNA is first ...